Payment overview · 2025
General Payments
$810.86
21 reported records · 9 companies
Healthcare provider profile · identity verified
Jorge A Gonzalez, DO
Allopathic & Osteopathic Physicians|Family Medicine · MIAMI BEACH, FL · NPI 1205922135
Verified facts
What the public records show
CMS Open Payments records show Jorge A Gonzalez, DO received $810.86 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $201.49 | 24.9% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $196.74 | 24.3% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $123.62 | 15.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.16 | 8.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.40 | 7.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.52 | 6.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $45.52 | 5.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.41 | 4.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.00 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $810.86 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $196.74 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $123.62 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.87 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.16 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $66.16 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.73 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.52 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.52 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45.52 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.41 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $26.89 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $25.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 120 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 196 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
120 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
98 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
196 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
231 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
249 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 757 | 236 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 621 | 190 |
| Alprazolam | Alprazolam | 533 | 87 |
| Losartan Potassium | Losartan Potassium | 501 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 496 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 470 | 133 |
| Metoprolol Succinate | Metoprolol Succinate | 466 | 139 |
| Omeprazole | Omeprazole | 438 | 129 |
| Pantoprazole Sodium | Pantoprazole Sodium | 425 | 141 |
| Gabapentin | Gabapentin | 366 | 114 |
| Famotidine | Famotidine | 347 | 108 |
| Metformin Hcl | Metformin Hcl | 307 | 94 |
| Ibuprofen | Ibuprofen | 273 | 64 |
| Lisinopril | Lisinopril | 260 | 80 |
| Eliquis | Apixaban | 249 | 52 |
| Furosemide | Furosemide | 245 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 77 |
| Clonazepam | Clonazepam | 234 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 234 | 90 |
| Ozempic | Semaglutide | 231 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 221 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 212 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 210 | 67 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 196 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 194 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 189 | 49 |
| Meloxicam | Meloxicam | 184 | 52 |
| Lorazepam | Lorazepam | 179 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 58 |
| Simvastatin | Simvastatin | 174 | 46 |
| Carvedilol | Carvedilol | 170 | 47 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 166 | 62 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 162 | 59 |
| Montelukast Sodium | Montelukast Sodium | 162 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 43 |
| Temazepam | Temazepam | 146 | 24 |
| Azithromycin | Azithromycin | 144 | 104 |
| Finasteride | Finasteride | 143 | 43 |
| Trazodone Hcl | Trazodone Hcl | 141 | 40 |
| Sertraline Hcl | Sertraline Hcl | 126 | 44 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 124 | 35 |
| Farxiga | Dapagliflozin Propanediol | 120 | 33 |
| Prednisone | Prednisone | 120 | 85 |
| Donepezil Hcl | Donepezil Hcl | 115 | 36 |
| Linzess | Linaclotide | 115 | 41 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 114 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 113 | 26 |
| Atenolol | Atenolol | 109 | 36 |
| Ketoconazole | Ketoconazole | 107 | 33 |
| Jardiance | Empagliflozin | 106 | 24 |
| Allopurinol | Allopurinol | 105 | 32 |
| Nifedipine Er | Nifedipine | 105 | 33 |
| Entresto | Sacubitril/Valsartan | 104 | 21 |
| Alendronate Sodium | Alendronate Sodium | 101 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 101 | 45 |
| Telmisartan | Telmisartan | 99 | 30 |
| Symbicort | Budesonide/Formoterol Fumarate | 98 | 25 |
| Labetalol Hcl | Labetalol Hcl | 96 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 31 |
| Methylprednisolone | Methylprednisolone | 95 | 73 |
| Myrbetriq | Mirabegron | 93 | 21 |
| Tramadol Hcl | Tramadol Hcl | 91 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 90 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 27 |
| Valsartan | Valsartan | 90 | 28 |
| Metformin Hcl Er | Metformin Hcl | 85 | 29 |
| Mirtazapine | Mirtazapine | 80 | 31 |
| Ventolin Hfa | Albuterol Sulfate | 80 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 79 | 24 |
| Latanoprost | Latanoprost | 78 | 21 |
| Ezetimibe | Ezetimibe | 77 | 26 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 76 | 22 |
| Potassium Chloride | Potassium Chloride | 76 | 22 |
| Celecoxib | Celecoxib | 75 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 20 |
| Amoxicillin | Amoxicillin | 72 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 24 |
| Pregabalin | Pregabalin | 70 | 15 |
| Memantine Hcl | Memantine Hcl | 69 | 26 |
| Trulicity | Dulaglutide | 68 | suppressed |
| Glipizide | Glipizide | 67 | 20 |
| Mounjaro | Tirzepatide | 67 | 15 |
| Spironolactone | Spironolactone | 66 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 65 | 17 |
| Folic Acid | Folic Acid | 64 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 64 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 63 | 30 |
| Sildenafil Citrate | Sildenafil Citrate | 63 | 14 |
| Fenofibrate | Fenofibrate | 61 | 16 |
| Gentamicin Sulfate | Gentamicin Sulfate | 60 | 35 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 59 | 24 |
| Megestrol Acetate | Megestrol Acetate | 58 | 14 |
| Vascepa | Icosapent Ethyl | 58 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 56 | 11 |
| Chlorthalidone | Chlorthalidone | 55 | 18 |
| Diclofenac Sodium Er | Diclofenac Sodium | 55 | suppressed |
| Hydrocortisone | Hydrocortisone | 55 | 24 |
| Ciclopirox | Ciclopirox | 54 | 18 |
| Xarelto | Rivaroxaban | 54 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 16 |
| Meclizine Hcl | Meclizine Hcl | 53 | 20 |
| Acyclovir | Acyclovir | 52 | 15 |
| Baclofen | Baclofen | 52 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 51 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 45 |
| Torsemide | Torsemide | 49 | 21 |
| Creon | Lipase/Protease/Amylase | 48 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 48 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Mupirocin | Mupirocin | 47 | 27 |
| Gemtesa | Vibegron | 46 | 15 |
| Glipizide Er | Glipizide | 45 | 16 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Bumetanide | Bumetanide | 44 | 12 |
| Lactulose | Lactulose | 44 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 43 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 12 |
| Synthroid | Levothyroxine Sodium | 43 | 13 |
| Glimepiride | Glimepiride | 41 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 36 |
| Clobetasol Propionate | Clobetasol Propionate | 40 | 13 |
| Januvia | Sitagliptin Phosphate | 40 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 38 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 19 |
| Repaglinide | Repaglinide | 38 | suppressed |
| Cefdinir | Cefdinir | 37 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 20 |
| Desloratadine | Desloratadine | 36 | 21 |
| Levofloxacin | Levofloxacin | 35 | 25 |
| Pentoxifylline | Pentoxifylline | 34 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 33 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 33 | 13 |
| Ammonium Lactate | Ammonium Lactate | 32 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 32 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | 14 |
| Ciclopirox | Ciclopirox Olamine | 31 | 17 |
| Irbesartan | Irbesartan | 31 | 12 |
| Valacyclovir | Valacyclovir Hcl | 31 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | 13 |
| Tradjenta | Linagliptin | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 29 | suppressed |
| Ranolazine Er | Ranolazine | 29 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Cephalexin | Cephalexin | 26 | 20 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 26 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | 11 |
| Tadalafil | Tadalafil | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 14 |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | 14 |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | 11 |
| Nateglinide | Nateglinide | 20 | suppressed |
| Ofloxacin | Ofloxacin | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 16 |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Lumigan | Bimatoprost | 17 | suppressed |
| Mesalamine | Mesalamine | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Galantamine Er | Galantamine Hbr | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Pindolol | Pindolol | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Primidone | Primidone | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Diovan | Valsartan | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Proctosol-Hc | Hydrocortisone | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $810.86 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, DUPIXENT, FARXIGA, FREESTYLE LIBRE 3, MOUNJARO, NURTEC ODT, TRELEGY ELLIPTA, WATCHMAN FLX, XIFAXAN, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error